207 related articles for article (PubMed ID: 21055615)
41. Biodistribution, Pharmacokinetics and Efficacy of
Chen LC; Lee WC; Ho CL; Chang YJ; Chen SJ; Chang CH
In Vivo; 2018; 32(3):567-573. PubMed ID: 29695562
[TBL] [Abstract][Full Text] [Related]
42. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
[TBL] [Abstract][Full Text] [Related]
43. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability.
Mukai T; Suwada J; Sano K; Okada M; Yamamoto F; Maeda M
Bioorg Med Chem; 2009 Jul; 17(13):4285-9. PubMed ID: 19481944
[TBL] [Abstract][Full Text] [Related]
44. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system.
Petrik M; Knetsch PA; Knopp R; Imperato G; Ocak M; von Guggenberg E; Haubner R; Silbernagl R; Decristoforo C
Nucl Med Commun; 2011 Oct; 32(10):887-95. PubMed ID: 21876399
[TBL] [Abstract][Full Text] [Related]
45. Production of glass microspheres comprising 90Y and (177)Lu for treating of hepatic tumors with SPECT imaging capabilities.
Poorbaygi H; Reza Aghamiri SM; Sheibani S; Kamali-Asl A; Mohagheghpoor E
Appl Radiat Isot; 2011 Oct; 69(10):1407-14. PubMed ID: 21723135
[TBL] [Abstract][Full Text] [Related]
46. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals.
Majkowska-Pilip A; Bilewicz A
J Inorg Biochem; 2011 Feb; 105(2):313-20. PubMed ID: 21194633
[TBL] [Abstract][Full Text] [Related]
47. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.
De Decker M; Turner JH
Cancer Biother Radiopharm; 2012 Feb; 27(1):72-6. PubMed ID: 22149590
[TBL] [Abstract][Full Text] [Related]
48. Clinically Applicable Cyclotron-Produced Gallium-68 Gives High-Yield Radiolabeling of DOTA-Based Tracers.
Jussing E; Milton S; Samén E; Moein MM; Bylund L; Axelsson R; Siikanen J; Tran TA
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439784
[TBL] [Abstract][Full Text] [Related]
49. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
50. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.
Le Fur M; Beyler M; Lepareur N; Fougère O; Platas-Iglesias C; Rousseaux O; Tripier R
Inorg Chem; 2016 Aug; 55(16):8003-12. PubMed ID: 27486673
[TBL] [Abstract][Full Text] [Related]
51. Pyridine-containing octadentate ligand NE3TA-PY for formation of neutral complex with
Chong HS; Chen Y; Kang CS; Sin I; Zhang S; Wang H
J Inorg Biochem; 2021 Aug; 221():111436. PubMed ID: 33971521
[TBL] [Abstract][Full Text] [Related]
52. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.
Asti M; Tegoni M; Farioli D; Iori M; Guidotti C; Cutler CS; Mayer P; Versari A; Salvo D
Nucl Med Biol; 2012 May; 39(4):509-17. PubMed ID: 22172388
[TBL] [Abstract][Full Text] [Related]
53. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo.
Hoffend J; Mier W; Schuhmacher J; Schmidt K; Dimitrakopoulou-Strauss A; Strauss LG; Eisenhut M; Kinscherf R; Haberkorn U
Nucl Med Biol; 2005 Apr; 32(3):287-92. PubMed ID: 15820764
[TBL] [Abstract][Full Text] [Related]
54.
Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
[TBL] [Abstract][Full Text] [Related]
55. Ga(III) chelates of amphiphilic DOTA-based ligands: synthetic route and in vitro and in vivo studies.
Fontes A; Prata MI; Geraldes CF; André JP
Nucl Med Biol; 2011 Apr; 38(3):363-70. PubMed ID: 21492785
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and
Altai M; Westerlund K; Velletta J; Mitran B; Honarvar H; Karlström AE
Nucl Med Biol; 2017 Nov; 54():1-9. PubMed ID: 28810153
[TBL] [Abstract][Full Text] [Related]
57. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
Wojdowska W; Karczmarczyk U; Maurin M; Garnuszek P; Mikołajczak R
Curr Radiopharm; 2015; 8(1):62-8. PubMed ID: 25506704
[TBL] [Abstract][Full Text] [Related]
58. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity.
Velikyan I; Beyer GJ; Långström B
Bioconjug Chem; 2004; 15(3):554-60. PubMed ID: 15149183
[TBL] [Abstract][Full Text] [Related]
59. Labelling of commercially available human serum albumin kits with 68Ga as surrogates for 99mTc-MAA microspheres.
Maus S; Buchholz HG; Ament S; Brochhausen C; Bausbacher N; Schreckenberger M
Appl Radiat Isot; 2011 Jan; 69(1):171-5. PubMed ID: 20880714
[TBL] [Abstract][Full Text] [Related]
60. 68Ga 'vacuum elution approach' for direct radiolabelling of DOTA-conjugated and NODAGA-conjugated peptides.
Ben Azzouna R; Leygnac S; Al-Shoukr F; Rouzet F; Guilloteau D; Le Guludec D
Nucl Med Commun; 2017 Jan; 38(1):51-56. PubMed ID: 27824725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
